Stocks
Genmab A/S American Depositary SharesGMABY
HealthcareBiotechnology
A biopharmaceutical company focused on the development and commercialization of antibody therapeutics for cancer and other serious diseases. Its lead product, Darzalex (daratumumab), is a blockbuster treatment for multiple myeloma, and the pipeline includes bispecific antibodies and antibody-drug conjugates. Investors track Genmab for its strong royalty stream from partnerships with Johnson & Johnson and its late-stage oncology pipeline.
Congressional Interest in Genmab A/S American Depositary Shares (GMABY)
1 member of Congress has disclosed 1 trade in Genmab A/S American Depositary Shares (GMABY), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading GMABY?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2019-05-28 | Mikie Sherrill | sell | $1K-$15K |